Spencer Pharma noch investieren ? - 500 Beiträge pro Seite
eröffnet am 30.08.10 14:38:08 von
neuester Beitrag 30.08.10 15:27:28 von
neuester Beitrag 30.08.10 15:27:28 von
Beiträge: 4
ID: 1.159.616
ID: 1.159.616
Aufrufe heute: 0
Gesamt: 151
Gesamt: 151
Aktive User: 0
ISIN: US8482241010 · WKN: A0YBXG · Symbol: SPPH
0,0000
USD
0,00 %
0,0000 USD
Letzter Kurs 08.03.24 Nasdaq OTC
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,9998 | +169,42 | |
| 1,0000 | +33,33 | |
| 0,5500 | +22,22 | |
| 15,348 | +19,53 | |
| 1,6500 | +17,86 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,5001 | -17,43 | |
| 5,2500 | -19,23 | |
| 5,2300 | -20,64 | |
| 1,3500 | -25,82 | |
| 0,7800 | -29,73 |
Feedback
Spencer Pharma - Aktie
WKN: A0YBXG | ISIN: US8482241010 | SPPH
WKN: A0YBXG | ISIN: US8482241010 | SPPH
August 30, 2010 - 6:30 AM EDT
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
SPPH 0.35 0.03
Today 5d 1m 3m 1y 5y 10y
Spencer Pharmaceutical Appoints Critical Member to Its Scientific Advisory Board
Spencer Pharmaceutical Appoints Critical Member to Its Scientific Advisory Board
BOSTON, MA, Aug. 30, 2010 (Marketwire) --
BOSTON, MA -- (Marketwire) -- 08/30/10 -- Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announces the appointment of Dr. Le Tien Canh, PhD to its Scientific Advisory Board.
Dr. Canh brings a diversified field of research knowledge to the team. He has been leading the research team at the University of Quebec at Montreal (UQAM) in the development of its Diabetes (Metformin), "Controlled Release Delivery System."
Dr. Canh is a research scientist with a wide field of academic experience (M.SC. in Biology, M.Sc. in Chemistry and Ph.D. in Biochemistry) with diversified experience in both academic and the industrial sectors. Some of his previous professional positions include VP and Director Research Development for several biopharmaceutical companies. He specializes in various domains such as pharmaceutics, biomedical, and food nutrition. Dr. Canh is author of numerous patents, related to novel biotechnologies, biomaterials and medicinal products. His research targets the innovative technologies for oral pharmaceutical drugs based on peptides or proteins.
"Having both Dr. Mircea Mateescu (announced June 15, 2010) and Dr. Canh on the Spencer Pharmaceutical advisory board and leading the Company's research goals are all positives in our collective efforts to successfully commercialize our technologies. We warmly welcome Dr. Canh," stated Mr. Ian Morrice, EVP and Director of Spencer Pharmaceutical Inc. Furthermore, "Although we originally targeted Diabetes, our proprietary technology also applies to the multibillion dollar generic drug market," reiterated Mr. Morrice.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.
Contact:
Dr. Max Arella
President
Spencer Pharmaceutical Inc.
1+(617) 973-5017
Source: Marketwire (August 30, 2010 - 6:30 AM EDT)
News by QuoteMedia
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
SPPH 0.35 0.03
Today 5d 1m 3m 1y 5y 10y
Spencer Pharmaceutical Appoints Critical Member to Its Scientific Advisory Board
Spencer Pharmaceutical Appoints Critical Member to Its Scientific Advisory Board
BOSTON, MA, Aug. 30, 2010 (Marketwire) --
BOSTON, MA -- (Marketwire) -- 08/30/10 -- Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announces the appointment of Dr. Le Tien Canh, PhD to its Scientific Advisory Board.
Dr. Canh brings a diversified field of research knowledge to the team. He has been leading the research team at the University of Quebec at Montreal (UQAM) in the development of its Diabetes (Metformin), "Controlled Release Delivery System."
Dr. Canh is a research scientist with a wide field of academic experience (M.SC. in Biology, M.Sc. in Chemistry and Ph.D. in Biochemistry) with diversified experience in both academic and the industrial sectors. Some of his previous professional positions include VP and Director Research Development for several biopharmaceutical companies. He specializes in various domains such as pharmaceutics, biomedical, and food nutrition. Dr. Canh is author of numerous patents, related to novel biotechnologies, biomaterials and medicinal products. His research targets the innovative technologies for oral pharmaceutical drugs based on peptides or proteins.
"Having both Dr. Mircea Mateescu (announced June 15, 2010) and Dr. Canh on the Spencer Pharmaceutical advisory board and leading the Company's research goals are all positives in our collective efforts to successfully commercialize our technologies. We warmly welcome Dr. Canh," stated Mr. Ian Morrice, EVP and Director of Spencer Pharmaceutical Inc. Furthermore, "Although we originally targeted Diabetes, our proprietary technology also applies to the multibillion dollar generic drug market," reiterated Mr. Morrice.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.
Contact:
Dr. Max Arella
President
Spencer Pharmaceutical Inc.
1+(617) 973-5017
Source: Marketwire (August 30, 2010 - 6:30 AM EDT)
News by QuoteMedia
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 165 | ||
| 78 | ||
| 73 | ||
| 70 | ||
| 65 | ||
| 53 | ||
| 52 | ||
| 45 | ||
| 38 | ||
| 36 |
| Wertpapier | Beiträge | |
|---|---|---|
| 31 | ||
| 24 | ||
| 24 | ||
| 23 | ||
| 20 | ||
| 19 | ||
| 18 | ||
| 18 | ||
| 18 | ||
| 17 |
